Vermont has posted three consecutive years of declining overdose deaths, which is rare when compared with national trends. In fact, opioid-involved deaths fell to 121 in 2025 from 183 in 2024, itself a 22 percent drop from 2023’s 236 deaths. Fortunately, xylazine, a veterinary sedative that resists naloxone, saw an even steeper decline, with its involvement in fatal overdoses falling 67 percent in a single year. Fentanyl, however, remains the dominant substance, present in 93 percent of Vermont’s opioid-related deaths in 2024, when it was almost always in combination with cocaine or xylazine rather than alone.
The state was also among the first to legalize overdose prevention centers, doing so in 2024, though Burlington’s planned site remains in the planning stage. Anyone researching detox should know the state’s treatment system leans heavily on primary care integration through Hub and Spoke, meaning a person’s regular doctor’s office may already be equipped to start treatment before a formal detox referral is even needed.
Vermont’s Department of Health, Division of Substance Use (DSU) certifies the state’s substance use disorder treatment providers under its Substance Use Disorder Treatment Certification Rule, with compliance assessed through regular site visits. The Department of Vermont Health Access (DVHA) administers Medicaid funding for treatment, including the bundled payment structure behind Vermont’s nationally recognized Hub and Spoke system of care.
